EGFR and metastatic malignant neoplasm: LY3164530 is a bispecific anti-EGFR/c-MET antibody produced by fusing an anti-EGFR single-chain variable fragment to the N-terminal end of the emibetuzumab heavy chain.1226 LY3164530 disrupts signaling by binding and internalizing c-MET and EGFR.1226 Its phase I clinical trial in patients with advanced or metastatic cancer has been completed.